Sangamo Therapeutics (SGMO) Leases (2019 - 2025)
Historic Leases for Sangamo Therapeutics (SGMO) over the last 7 years, with Q3 2025 value amounting to $14.4 million.
- Sangamo Therapeutics' Leases fell 1878.87% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 1878.87%. This contributed to the annual value of $16.9 million for FY2024, which is 3509.68% down from last year.
- As of Q3 2025, Sangamo Therapeutics' Leases stood at $14.4 million, which was down 1878.87% from $15.1 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Leases ranged from a high of $73.2 million in Q4 2021 and a low of $14.4 million during Q3 2025
- Moreover, its 5-year median value for Leases was $46.8 million (2023), whereas its average is $42.8 million.
- As far as peak fluctuations go, Sangamo Therapeutics' Leases skyrocketed by 300.65% in 2021, and later tumbled by 6007.95% in 2024.
- Sangamo Therapeutics' Leases (Quarter) stood at $73.2 million in 2021, then fell by 15.28% to $62.0 million in 2022, then tumbled by 58.08% to $26.0 million in 2023, then tumbled by 35.1% to $16.9 million in 2024, then fell by 14.47% to $14.4 million in 2025.
- Its last three reported values are $14.4 million in Q3 2025, $15.1 million for Q2 2025, and $16.0 million during Q1 2025.